Strategic Capital Raising Pathways: Choosing the Right Structure for Growth
- Adam Koscielski
- Mar 24
- 4 min read
In this blog we discuss how SAFEs, convertible notes, and equity rounds impact dilution, control, and future financing. Learn how to structure capital the right way.
How you raise capital shapes everything that comes after.
Capital raising is often treated as a milestone—a box to check. In reality, it's one of the most consequential structural decisions a company makes.
Across early-stage financings, growth rounds, and complex regulated deals, the structure you choose determines:
How ownership evolves
Who controls key decisions
How easy (or difficult) future financings will be
At a high level, most companies raise capital through one of three pathways: SAFEs, convertible notes, or priced equity. Each strategic capital raising pathway serves a purpose, but each also carries tradeoffs that are often misunderstood at the outset.
SAFEs (Simple Agreements for Future Equity)
A SAFE is an agreement where an investor gives a company money today in exchange for the right to receive equity at a later date, typically when the company raises a priced round.
There is no loan, no interest, and no requirement to repay the money. Instead, the investment "converts" into shares in the future, usually at a discount or based on a valuation cap.
SAFEs were introduced to simplify early-stage fundraising by removing the need to negotiate valuation and full financing documents at the earliest stages. They are now widely used in early-stage and founder-led rounds, particularly when speed and efficiency matter.
SAFEs defer dilution but they don’t eliminate it. Instead of issuing equity today, dilution is pushed into the next priced round, where all SAFEs convert simultaneously. This can create a “shock” to the cap table, particularly if multiple SAFEs were issued at different valuation caps. Founders often underestimate how much ownership is given up because the dilution is not visible at the time of issuance. Market standard practice is to model conversion scenarios in advance, including best- and worst-case outcomes, to avoid unexpected ownership compression when the round closes.
Market Standard Terms
Valuation cap (maximum price at which the SAFE converts)
Discount to the next round price
Conversion upon a future financing event
No maturity date or repayment obligation
Where Deals Break
Multiple SAFEs issued at different caps (“stacking”)
Founders not modeling total dilution
Investors having different expectations due to limited structure
What Works Better
Model ownership outcomes before issuing SAFEs
Keep terms consistent across investors
Use SAFEs as a bridge—not a long-term capital strategy
Business Impact
SAFEs are fast and flexible, but they defer key decisions. If overused, they can create significant dilution and cap table complexity later.
Convertible Notes
A convertible note is a loan that is intended to convert into equity later. The investor lends money to the company, and instead of being repaid in cash, the loan converts into shares, typically when the company raises its next round.
Unlike a SAFE, this is real debt. That means it has a maturity date and accrues interest.
Convertible notes impact dilution in two ways: through conversion mechanics and time. Because notes accrue interest, the amount converting into equity increases over time if not paid, meaning dilution grows the longer conversion is delayed. Like SAFEs, dilution is deferred until a financing event, but unlike SAFEs, timing matters more due to maturity pressure. If multiple notes are outstanding with different terms, conversion can create uneven ownership outcomes and complicate the cap table. Proper modeling should account for interest accrual, timing of conversion, and how different instruments stack together.
Market Standard Terms
Interest rate (added to the investment before conversion)
Maturity date (when the loan must be repaid or converted)
Valuation cap and/or discount
Conversion triggers (e.g., qualified financing, change of control)
Where Deals Break
Maturity date arrives without a financing event
Company lacks cash to repay the loan
Investors gain leverage through default rights
What Works Better
Align maturity with realistic fundraising timelines
Build flexibility into extension or conversion mechanics
Use when timing of the next round is reasonably predictable
Business Impact
Convertible notes add structure and investor protection but also introduce pressure. If not managed carefully, they can force companies into rushed or unfavorable financings.
Priced Equity Rounds
A priced round is a traditional investment where the company sells shares to investors at an agreed valuation. Unlike SAFEs or notes, everything is defined upfront: how much the company is worth, how much ownership investors receive, and what rights they have.
Priced rounds create immediate and transparent dilution. Ownership percentages are set at closing, and the cap table is updated in real time. While this provides clarity, it also locks in dilution at a negotiated valuation, which means pricing discipline is critical. Beyond percentage ownership, dilution in priced rounds is also shaped by economic terms such as option pool refreshes, liquidation preferences, and participation rights. Market standard practice is to evaluate dilution not just on a percentage basis, but on a fully diluted, post-money basis that accounts for all outstanding and reserved equity.
Market Standard Structure
Priced rounds typically include:
A negotiated valuation
Issuance of equity (often preferred stock or membership interests)
Governance rights (e.g., board seats, voting thresholds)
Investor protections (e.g., liquidation preferences, veto rights)
Where Deals Break
Giving up too much control too early
Misalignment between founders and investors on governance
Terms that make future rounds harder to close
What Works Better
Balance capital needs with control concessions
Keep terms consistent with market expectations
Ensure the structure is financeable for future investors
Business Impact
Priced rounds provide clarity and alignment but they lock in ownership and control in ways that shape the company permanently.
Practical Takeaways
Choose structure based on stage, leverage, and investor profile
Model dilution before raising, not after
Understand how each instrument impacts future financings
Align expectations early. Structure won’t fix misalignment
Treat capital as a long-term strategic decision
Specific Considerations for Strategic Capital Raising in Cannabis
Capital structuring in cannabis requires additional analysis because regulators evaluate not just ownership, but influence and control.
Key Issues
Investor rights (even in debt instruments) may trigger control analysis
Ownership limits and license caps across affiliated entities
Disclosure requirements for lenders, noteholders, and passive investors
Regulatory approvals or notices tied to financing events
Market Reality
We regularly see financings delayed or restructured because rights negotiated in standard deals unintentionally trigger regulatory scrutiny.
Conclusion
Structuring capital correctly determines whether a company can scale, refinance, or exit without friction.
The right structure preserves flexibility, aligns incentives, and supports execution. The wrong one compounds constraints over time.
Greenbar works with founders, operators, and investors to design capital structures that function across growth, regulatory review, and exit.
Comments